Proportion of participants with persisting anemic symptoms (epigastric pain, weakness, dizziness) at two weeks after initial therapy
Persistent anemic symptoms were reported in 4.2% of the Mojeaga group and 8.5% of the control group (p = 0.329). There were no cases of treatment failure.